Multisystem Processes & Disorders

Surgical site infection: prevention and management

Clinical Overview and When to Suspect Surgical Site Infection

— Superficial incisional: skin and subcutaneous tissue only

— Deep incisional: fascia and muscle layers

— Organ/space: any anatomic structure manipulated during surgery (intra-abdominal abscess, mediastinitis, empyema, joint space)

— Class I clean (~1–2%), Class II clean-contaminated (~5–8%), Class III contaminated (~10–15%), Class IV dirty (>20%)

— New or worsening incisional pain after POD 3

— Erythema extending >2 cm beyond wound edges

— Purulent drainage, wound dehiscence, fluctuance

— Fever >38.5°C after POD 4 (early fever POD 0–2 is usually atelectasis or cytokine response, not infection)

— Unexplained tachycardia, leukocytosis, or failure to progress with diet/ambulation

— Skin/soft tissue, orthopedic, cardiac: S. aureus (incl. MRSA), CoNS

— GI/colorectal, gynecologic: polymicrobial—E. coli, Bacteroides, enterococci

— GU: gram-negatives

Board pearl: The classic "5 W's" of postop fever align with timing—Wind (POD 1–2 atelectasis/PNA), Water (POD 3–5 UTI), Walking (POD 4–6 DVT), Wound (POD 5–7 SSI), Wonder drugs (POD 7+). A patient febrile on POD 5–7 with incisional tenderness is SSI until proven otherwise.

Definition (CDC/NHSN): Infection occurring within 30 days of surgery (or within 90 days if an implant such as mesh, prosthetic joint, or vascular graft is left in place), related to the operative procedure.

Three anatomic tiers:

Epidemiology: SSIs complicate 2–5% of inpatient surgeries; leading cause of healthcare-associated infection in surgical patients, adding ~7–10 hospital days and substantial cost.

Wound classification predicts risk:

When to suspect SSI postoperatively:

Pathogens by site:

Host risk factors: diabetes (HbA1c >7), obesity (BMI >30), smoking, malnutrition (albumin <3.5), immunosuppression, prior radiation, active remote infection.

Presentation Patterns and Key History

— POD 5–7: classic superficial/deep incisional SSI (S. aureus, gram-negatives)

— POD <48 hours with severe pain, crepitus, hemodynamic instability: suspect necrotizing fasciitis or clostridial myonecrosis—surgical emergency

— Weeks to months postop with implant: indolent biofilm infection (CoNS, Cutibacterium acnes in shoulder arthroplasty)

— Up to 90 days for prosthetic/mesh procedures

— Increasing rather than decreasing incisional pain after POD 3

— Drainage (serous → serosanguinous → purulent progression is abnormal)

— Fever, chills, malaise

— Wound "opening up" or sutures cutting through

— Operative details: procedure type, wound class, duration (>2× expected ↑ risk), urgency, presence of implant

— Prophylactic antibiotic: drug, dose, timing of first dose (within 60 min of incision; 120 min for vancomycin/fluoroquinolones), redosing intervals

— Glycemic control: perioperative glucose >180–200 mg/dL doubles SSI risk

— Tobacco use: smoking within 4 weeks of surgery

— MRSA colonization or prior MRSA infection

— Preop bathing/clipping (not shaving) practices

— Postop care: dressing changes, wound exposure to water, home environment

— Pain out of proportion to exam

— Rapidly spreading erythema, bullae, dusky skin, crepitus

— Systemic signs: hypotension, AMS, oliguria → sepsis pathway

— Sternal wound instability after cardiac surgery (mediastinitis)

Step 3 management: In an ambulatory follow-up visit, a patient POD 6 from open ventral hernia repair with mesh reports new fever and incisional drainage—do not simply prescribe oral antibiotics by phone. Bring patient in, examine the wound, obtain cultures of drainage (not surface swab), and assess for fluctuance requiring opening. Phone-only management of suspected SSI is a documented transition-of-care safety gap.

Typical timeline:

Cardinal symptoms patients report:

High-yield history to elicit:

Red-flag features mandating immediate workup:

Physical Exam Findings and Hemodynamic Assessment

— Erythema: measure and mark the border with skin marker to track progression

— Edema, warmth, induration extending beyond incision

— Drainage: character (serous, serosanguinous, purulent, feculent, bilious), volume, odor

— Wound integrity: dehiscence, exposed fascia, visible bowel/viscera = evisceration (surgical emergency)

— Skin changes: bullae, dusky/violaceous discoloration, anesthesia of overlying skin → necrotizing infection

— Fluctuance suggests abscess requiring drainage

— Crepitus = gas-forming organism until proven otherwise (Clostridium, mixed anaerobes, group A strep)

— Point tenderness deep to incision suggests deep/organ-space involvement

— Sternal "click" or instability after median sternotomy → mediastinitis

— Joint effusion, restricted ROM, pain on micromotion → prosthetic joint infection

— Peritoneal signs (guarding, rebound) → intra-abdominal organ-space SSI

— Vitals: HR, BP, RR, temperature, SpO2, shock index (HR/SBP) >1.0 signals decompensation

— qSOFA ≥2 (RR ≥22, AMS, SBP ≤100) → sepsis workup

— Capillary refill, mottling, mental status

— Lymphangitic streaking, regional lymphadenopathy

Key distinction: Cellulitis vs. abscess vs. necrotizing infection at the surgical site drives next step:

— Cellulitis (erythema, no fluctuance, no systemic toxicity) → empiric antibiotics, mark border, 24-hr recheck

— Abscess/fluid collection → open the wound at bedside, drain, pack, culture

— Necrotizing infection (pain out of proportion, crepitus, bullae, septic shock, LRINEC ≥6) → emergent OR debridement plus broad-spectrum antibiotics; do not delay for imaging

Inspect the wound systematically:

Palpation:

Functional assessment:

Systemic and hemodynamic exam:

Documentation matters: Photograph (with consent) and measure wounds at each visit; documented progression drives both clinical decisions and medicolegal defense.

Diagnostic Workup — Initial Labs, Imaging, and Cultures

— CBC with differential: leukocytosis with left shift; leukopenia in severe sepsis

— BMP: AKI, hyperglycemia, acidosis (anion gap)

— Lactate: >2 suggests tissue hypoperfusion, >4 mandates aggressive resuscitation

— CRP and procalcitonin: CRP normally peaks POD 2–3 and falls; rising or sustained CRP after POD 4 suggests SSI. Procalcitonin useful to distinguish bacterial infection and guide duration

— LFTs, coags, type and screen if OR likely

— HbA1c if not recent—glycemic control directly affects healing

— Deep wound or aspirate culture, not superficial swab (surface swabs grow colonizers)

— Two sets of blood cultures before antibiotics if febrile, systemically ill, or implant present

— Gram stain on aspirate guides empiric choice (gram-positive cocci vs. mixed flora)

— Send anaerobic cultures and fungal cultures in immunocompromised or chronic wounds

— Plain films: soft tissue gas (necrotizing infection), free air after abdominal surgery

— Ultrasound: superficial fluid collection, abscess, guides drainage

— CT with IV contrast: gold standard for deep/organ-space SSI (intra-abdominal abscess, mediastinitis, pelvic collection)

— MRI: osteomyelitis, prosthetic joint infection, spinal SSI

— Echocardiography: if bacteremia with implant or murmur (endocarditis)

Board pearl: A surface swab of pus growing mixed flora including diphtheroids is essentially uninterpretable. The board-correct culture is a deep tissue specimen or aspirated fluid sent in anaerobic transport—drive treatment from that.

Bedside actions come first: open the wound if fluctuant or draining purulence, obtain deep tissue/fluid for culture before starting antibiotics when patient is stable.

Laboratory studies:

Cultures—do them right:

LRINEC score (necrotizing fasciitis risk): CRP, WBC, Hgb, Na, Cr, glucose; ≥6 suspicious, ≥8 high risk—but a low score does not rule out necrotizing infection clinically.

Imaging—targeted by site:

Diagnostic Workup — Advanced and Confirmatory Studies

— CT-guided percutaneous drainage is both diagnostic and therapeutic for intra-abdominal/pelvic abscess >3 cm—send fluid for Gram stain, aerobic/anaerobic culture, cell count

— Collections <3 cm or multiloculated may require surgical drainage

— Repeat imaging at 48–72 hr if no clinical improvement to assess catheter position and residual collection

— ESR >30 and CRP >10 mg/L have high sensitivity

— Synovial fluid aspiration: WBC >3,000/µL with PMN >80% (knee), alpha-defensin, leukocyte esterase strip

— Hold antibiotics at least 2 weeks before aspiration when feasible to maximize culture yield

— Intraoperative tissue cultures (≥3 samples, hold 14 days for Cutibacterium in shoulder)

— CT chest for retrosternal fluid, sternal dehiscence, mediastinal stranding

— Blood cultures essential; echocardiography to rule out endocarditis or graft infection

— MRSA nasal PCR: if negative, has high NPV for MRSA SSI and supports de-escalation off vancomycin

— 16S rRNA PCR of explanted tissue when cultures negative but suspicion high

— Sonication of explanted hardware improves yield by disrupting biofilm

Step 3 management: When CT shows a drainable collection in a stable patient, the right answer is almost always percutaneous drainage with culture-directed antibiotic therapy rather than empiric IV antibiotics alone. Source control is non-negotiable—antibiotics treat the periphery; drainage treats the disease.

Organ/space SSI confirmation:

Prosthetic joint infection workup:

Cardiac/sternal:

Vascular graft infection: CT angiography for perigraft fluid/gas, pseudoaneurysm; WBC-tagged scan or FDG-PET/CT when CT equivocal.

Mesh infection: ultrasound or CT for fluid around mesh; chronic sinus tracts may need fistulogram.

Spinal hardware infection: MRI with contrast; nuclear imaging if hardware artifact limits MRI.

Microbiologic adjuncts:

Risk Stratification and Prevention Bundle Logic

— Glycemic control: target perioperative glucose 110–180 mg/dL; defer elective surgery if HbA1c >8 when feasible

— Smoking cessation ≥4 weeks before elective surgery

— MRSA decolonization in high-risk surgeries (cardiac, orthopedic implant): intranasal mupirocin BID × 5 days + chlorhexidine bathing × 5 days

— Chlorhexidine-gluconate bathing night before and morning of surgery

— Hair removal: if necessary, use clippers immediately before incision—never razors (microabrasions ↑ SSI)

— Treat remote infections (UTI, dental) before elective procedures

— Nutritional optimization: prealbumin, oral immunonutrition in malnourished GI surgery patients

— Antibiotic prophylaxis within 60 minutes of incision (120 min for vancomycin/fluoroquinolones); redose for procedures >2 half-lives or blood loss >1500 mL

— Skin prep: alcohol-based chlorhexidine preferred over povidone-iodine for most procedures (not mucosa)

— Normothermia (core temp >36°C)—forced-air warming

— Normoxia: FiO₂ 0.8 intraoperatively and 2–6 hr postop in colorectal surgery (controversial but in guidelines)

— Maintain euvolemia; minimize transfusion

— Closed-suction drains only when indicated; remove early

— Sterile dressing 48 hours, then wound may be exposed to water

— Continue glucose control, early ambulation, nutrition

Board pearl: Discontinue prophylactic antibiotics within 24 hours of incision close (48 hr for cardiac surgery per some protocols; current AHA/SCIP guidance favors 24 hr). Continuing prophylaxis "while the drain is in" or "until the Foley comes out" is a frequent wrong answer—it does not reduce SSI and promotes C. difficile and resistance.

Preoperative prevention—high-yield bundle:

Intraoperative prevention:

Postoperative prevention:

Pharmacotherapy — Prophylactic and Empiric Regimens

— Clean (orthopedic, cardiac, vascular, neurosurgery, breast): cefazolin 2 g IV (3 g if >120 kg)

— Colorectal: cefazolin + metronidazole, OR cefoxitin, OR ertapenem; oral neomycin + erythromycin (or metronidazole) the day before with mechanical bowel prep reduces SSI

— Hysterectomy/C-section: cefazolin; add azithromycin for non-elective C-section

— Head and neck (clean-contaminated): ampicillin-sulbactam or clindamycin

— GU: cefazolin; ciprofloxacin if prostate biopsy

— Non-severe (rash only, remote): still give cefazolin—cross-reactivity <2%

— Severe/anaphylaxis: clindamycin or vancomycin ± aminoglycoside or aztreonam for gram-negative coverage

— Superficial incisional, no systemic toxicity, no MRSA risk: open the wound, often no antibiotics needed; cephalexin or TMP-SMX if cellulitis

— MRSA-risk cellulitis: TMP-SMX, doxycycline, clindamycin, or linezolid

— Deep/organ-space, systemic toxicity: vancomycin + piperacillin-tazobactam (or cefepime + metronidazole)

— Necrotizing infection: vancomycin + piperacillin-tazobactam + clindamycin (clinda blocks toxin production)

— Intra-abdominal SSI: piperacillin-tazobactam or carbapenem; add antifungal if Candida on Gram stain or recurrent perforation

Step 3 management: A patient develops a draining wound POD 6—open it, culture deep tissue, and reserve antibiotics for cellulitis or systemic signs. Antibiotics without drainage is the most common wrong answer on SSI vignettes.

Prophylactic antibiotic selection by procedure:

MRSA coverage indications: add vancomycin 15 mg/kg IV if MRSA-colonized, prior MRSA infection, institutional MRSA rates >10–20%, or implant in high-risk patient

β-lactam allergy:

Empiric treatment of established SSI:

De-escalation: narrow within 48–72 hr based on cultures; duration typically 4–7 days after adequate source control (STOP-IT trial for intra-abdominal).

Procedural and Surgical Management

— Remove staples/sutures over the affected area

— Express purulence, irrigate copiously with normal saline (povidone-iodine retards healing in open wounds)

— Probe for fascial integrity—intact fascia = superficial/deep incisional; dehisced fascia = surgical emergency

— Pack with saline-moistened gauze or use negative-pressure wound therapy (NPWT/wound vac) for large defects

— Plan healing by secondary intention or delayed primary closure

— Necrotizing soft tissue infection (serial debridement every 12–24 hr until clean margins)

— Fascial dehiscence/evisceration

— Mediastinitis (sternal debridement, rewiring vs. muscle flap)

— Infected prosthetic joint, mesh, or vascular graft when source control mandates removal

— Early PJI (<3–4 weeks postop, stable implant): debridement, antibiotics, and implant retention (DAIR) with polyethylene exchange

— Late or chronic PJI: two-stage exchange (remove hardware, antibiotic spacer × 6 weeks IV antibiotics, then reimplant)—gold standard in US

— Infected vascular graft: excision with extra-anatomic bypass or in-situ reconstruction with cryopreserved/rifampin-soaked graft

— Infected mesh: often requires partial or complete explantation if chronic sinus or systemic infection

CCS pearl: For a febrile postop patient with a fluctuant wound, the order set is: open and culture wound → blood cultures → CBC, lactate, BMP → IV access, fluids → empiric antibiotics if systemic toxicity → imaging if deep extension suspected → consult surgery early. Advance the clock and reassess.

Bedside wound opening (the workhorse intervention):

Drain placement: percutaneous drainage by IR for deep collections; surgical drainage for complex/multiloculated abscesses or when percutaneous fails

Operative debridement indications:

Implant management decisions:

NPWT advantages: ↓ edema, ↑ granulation, ↓ dressing changes; contraindicated over exposed vessels/bowel without protection

Closure strategy: delayed primary closure once granulation is clean; complex wounds may need flap coverage (plastics consult)

Special Populations — Elderly and Renal/Hepatic Impairment

— Blunted febrile response—absence of fever does not exclude SSI; rely on delirium, anorexia, functional decline, tachycardia

— Higher baseline frailty; SSI dramatically ↑ 30-day mortality and loss of independence

— Skin fragility complicates dressing changes; consider silicone-bordered dressings

— Polypharmacy raises risk of antibiotic–drug interactions (warfarin + TMP-SMX; statins + macrolides)

— Aggressive delirium prevention during inpatient SSI treatment

— Vancomycin: dose by AUC/MIC (target 400–600 mg·hr/L) rather than trough alone; reduce frequency in CKD; monitor trough and creatinine every 2–3 days

— Piperacillin-tazobactam + vancomycin: synergistic nephrotoxicity—consider cefepime + metronidazole as alternative in CKD

— Aminoglycosides: avoid when possible; if used, extended-interval dosing with levels

— TMP-SMX: hyperkalemia and pseudo-creatinine rise; avoid with ACEi/ARB in advanced CKD

— Linezolid: renally safe but thrombocytopenia with prolonged use

— Avoid nephrotoxic contrast when possible; if imaging needed, use isotonic hydration

— Metronidazole, clindamycin, linezolid, tigecycline: dose-reduce or monitor in Child-Pugh B/C

— Avoid prolonged β-lactams with cholestatic potential (ceftriaxone biliary sludging)

— Coagulopathy increases bleeding risk with bedside wound opening—correct INR/platelets before deep procedures

— Hypoalbuminemia worsens wound healing and increases free fraction of highly protein-bound drugs

Key distinction: A creatinine that bumps from 1.0 to 1.4 on TMP-SMX or tenofovir may reflect tubular secretion inhibition rather than true AKI—check cystatin C or recheck off the drug before assuming nephrotoxicity, but still adjust dosing per measured eGFR.

Elderly patients:

Renal impairment:

Hepatic impairment:

Dialysis patients: dose vancomycin after hemodialysis; cefazolin 2 g IV after each session is a reasonable empiric backbone for gram-positives.

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— C-section SSI rate 3–15%, higher with emergent surgery, chorioamnionitis, obesity, prolonged ROM

— Prophylaxis: cefazolin before skin incision (not after cord clamp—reduces maternal infection without harm to neonate); add azithromycin for non-elective cesarean

— Chlorhexidine or povidone-iodine vaginal prep before cesarean reduces endometritis

— Postpartum endometritis: clindamycin + gentamicin IV until afebrile 24–48 hr; no oral step-down required if afebrile

— Safe antibiotics in pregnancy: β-lactams, clindamycin, erythromycin; avoid tetracyclines, fluoroquinolones, TMP-SMX in 1st/3rd trimester

— Weight-based dosing critical (cefazolin 30 mg/kg)

— Higher proportion of MSSA; vancomycin reserved for confirmed MRSA or severe illness

— Congenital heart surgery: meticulous mediastinitis surveillance

— Wound care psychology—age-appropriate explanation, distraction, Child Life consult

— Attenuated inflammatory signs—erythema may be minimal even with deep infection

— Broader empiric coverage including gram-negatives, fungi, and atypical organisms

— Hold/adjust immunosuppression in consultation with primary specialist (e.g., reduce calcineurin inhibitor dose, hold mycophenolate, hold TNF-α inhibitor during active infection)

— Consider β-D-glucan, galactomannan, fungal cultures

— Longer treatment durations; lower threshold for surgical source control

Board pearl: A transplant patient on tacrolimus and prednisone with an "unremarkable" surgical wound but persistent low-grade fever and rising CRP—image early and culture aggressively; the classic erythema/induration may never appear.

Pregnancy and obstetric SSI:

Pediatric SSI:

Immunocompromised (transplant, chemotherapy, HIV, chronic steroids, biologics):

Diabetes: target perioperative glucose 110–180; insulin infusion in poorly controlled inpatients; resume basal-bolus before discharge.

Obesity: higher cefazolin dose (3 g if >120 kg), redose for prolonged surgery; consider weight-based vancomycin.

Complications and Adverse Outcomes

— Wound dehiscence: partial (skin only) vs. fascial dehiscence with evisceration—the latter requires emergent OR, NPO, IV fluids, broad-spectrum antibiotics, and saline-moistened sterile gauze over exposed viscera in transport

— Chronic non-healing wound → may require flap coverage, hyperbaric oxygen in selected cases

— Fistula formation: enterocutaneous, biliary, urinary—nutrition optimization, source control

— Incisional hernia: late complication after SSI/dehiscence

— Hypertrophic scar or keloid

— Sepsis and septic shock: Hour-1 bundle—lactate, blood cultures, broad-spectrum antibiotics, 30 mL/kg crystalloid for hypotension or lactate ≥4, vasopressors (norepinephrine first-line)

— Bacteremia and metastatic infection: endocarditis, epidural abscess, septic arthritis (especially with S. aureus bacteremia—always obtain TTE, repeat blood cultures, 14-day minimum IV therapy)

— Acute kidney injury from sepsis or nephrotoxic antibiotics

— C. difficile colitis from broad-spectrum antibiotics—stop unnecessary antibiotics, oral vancomycin or fidaxomicin

— Drug reactions: vancomycin-related DRESS, AKI; β-lactam rash

— Prosthetic joint loosening, periprosthetic fracture, persistent draining sinus

— Vascular graft pseudoaneurysm, hemorrhage, limb loss

— Mediastinitis with sternal nonunion

— Functional decline, prolonged disability, depression

— Recurrent infection at site

— Increased mortality—deep/organ-space SSI 2–11× ↑ 30-day mortality

Step 3 management: A patient with S. aureus bacteremia from a wound infection requires ID consult, source control, repeat blood cultures every 48 hr until clear, echocardiography (TTE → TEE if implant or persistent bacteremia), and minimum 14 days of IV therapy from first negative culture—2-week course is the floor, not the ceiling.

Local complications:

Systemic complications:

Implant-related:

Long-term sequelae:

System-level: readmission within 30 days (CMS quality metric), reimbursement penalties, malpractice exposure.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Outpatient management: afebrile, hemodynamically stable, superficial SSI, reliable patient, oral antibiotics tolerated, daily wound care feasible, follow-up in 48–72 hr

— Inpatient ward: systemic signs but stable, requires IV antibiotics, NPWT initiation, deeper wound exploration, IR drainage

— Step-down or ICU: sepsis with vasopressor need, lactate >4, AMS, AKI, respiratory failure, necrotizing infection, mediastinitis, postop hemodynamic instability

— Suspected necrotizing soft tissue infection

— Fascial dehiscence or evisceration

— Deep/organ-space SSI requiring debridement

— Infected implant, mesh, vascular graft, or hardware

— Failure to improve on 48–72 hr of antibiotics with adequate source control

— Mediastinitis, intra-abdominal abscess, prosthetic joint infection

— Infectious disease: bacteremia, multidrug-resistant organisms, immunocompromise, prolonged IV therapy planning, implant infection

— Interventional radiology: percutaneous drainage of deep collections

— Plastic surgery: complex wound coverage, flap reconstruction

— Wound care/ostomy nurse: NPWT management, complex dressings, ostomy adjacent wounds

— Nutrition: albumin <3, prolonged NPO, malnutrition screening positive

— SBP <90 or MAP <65 after 30 mL/kg crystalloid

— Lactate >4 mmol/L or persistent >2 after resuscitation

— Vasopressor requirement

— Respiratory failure (SpO2 <92% on supplemental O2, RR >30)

— AMS, GCS drop

— Severe metabolic acidosis (pH <7.2)

— Need for OPAT planning with concurrent organ dysfunction

CCS pearl: On the CCS case, don't forget to order vital signs every shift, daily wound exams, daily CBC/BMP, lactate trending, blood culture clearance every 48 hr, and reassess antibiotics at 48–72 hr for de-escalation. The case "advances the clock"—you must reassess at each interval.

Disposition decision tree:

Surgical consult immediately for:

Other consults:

ICU triggers (any one):

Key Differentials — Same-Category Postoperative Infections

— Pneumonia/atelectasis (Wind): POD 1–3, low-grade fever, decreased breath sounds, basal opacities on CXR—not SSI

— Urinary tract infection (Water): POD 3–5, dysuria, suprapubic tenderness, indwelling Foley—UA, urine culture

— Catheter-associated bloodstream infection (CLABSI): central line in place, fever without localizing source, positive blood cultures with skin flora; differential time-to-positivity from line vs. peripheral suggests source

— C. difficile colitis: POD 3+, diarrhea after broad-spectrum antibiotics, leukocytosis (often striking)—stool toxin/PCR

— Anastomotic leak (after GI surgery): POD 5–7, fever, tachycardia, abdominal pain, ileus, leukocytosis—CT with oral/rectal contrast; surgical emergency, may present as organ-space SSI

— Aspiration pneumonitis vs. pneumonia: early respiratory symptoms postop

— Wound exam normal but fever present → look elsewhere first; UA, CXR, blood cultures, line exam

— Diarrhea + leukocytosis → C. diff PCR before assuming SSI

— Persistent tachycardia and abdominal pain despite normal-appearing wound after bowel surgery → anastomotic leak is the can't-miss

— Drug fever (POD 7+ from antibiotics, eosinophilia, well-appearing)

— DVT/PE (Walking; POD 4–6, unilateral leg edema, hypoxia)

— Transfusion reaction

— Hematoma (looks like wound infection but no purulence, often resolves)

— Seroma (sterile fluid collection, no erythema or systemic signs—may need drainage if symptomatic)

Key distinction: Hematoma vs. abscess vs. seroma at the wound:

— Hematoma: early postop, bluish discoloration, no fever, evolves over days

— Seroma: painless fluctuance, clear-yellow on aspirate, sterile

— Abscess: erythema, warmth, fever, purulent on aspirate, leukocytosis

Send aspirate for cell count, Gram stain, and culture before committing to a diagnosis.

Postoperative fever differential (same infectious category as SSI):

Distinguishing features:

Mimics that can coexist with SSI:

Key Differentials — Other-Category Postoperative Causes

— POD 0–2 fever is most often inflammatory; if patient looks well and exam is unremarkable, observe without pan-culturing

— Atelectasis as fever cause is overstated—usually represents undertreated pain limiting ventilation

— DVT/PE (POD 4–6): unilateral calf swelling, pleuritic chest pain, hypoxia, sinus tachycardia, S1Q3T3 on ECG → CT pulmonary angiogram, duplex US, anticoagulation

— Postop patients are high-risk; ensure VTE prophylaxis was given

— Drug fever: ~POD 7+, well-appearing despite fever, may have rash, eosinophilia; common with β-lactams, sulfa, anticonvulsants

— Serotonin syndrome, NMS, malignant hyperthermia: anesthesia-related, early postop, autonomic instability, rigidity

— Alcohol or benzodiazepine withdrawal: POD 2–4, tachycardia, hypertension, tremor, AMS—history-dependent

— Adrenal insufficiency in chronic steroid users not given stress-dose—hypotension, hyponatremia, hypoglycemia

— Thyroid storm post-thyroidectomy in inadequately blocked patient

— DKA/HHS in poorly controlled diabetic

— MI, atrial fibrillation, pericarditis (post-cardiac surgery); ECG and troponin

— Dressler's syndrome later post-MI/cardiac surgery

— Acalculous cholecystitis in critically ill postop patients—RUQ US

— Bowel ischemia post-vascular or cardiac surgery—lactate, CT angiography

— Transfusion reaction during/shortly after blood products

— Wound endometriosis at C-section scar (cyclic pain, not infection)

Board pearl: A postop patient on chronic prednisone ≥5 mg daily for >3 weeks undergoing major surgery needs stress-dose steroids (hydrocortisone 50–100 mg IV q8h tapered over 1–3 days). Failure to dose, presenting as refractory hypotension with normal-appearing wound, is a classic Step 3 vignette mistaken for septic SSI.

Non-infectious postoperative fever (cytokine release):

Thromboembolic disease:

Drug-related:

Endocrine and metabolic:

Cardiovascular:

Other:

Secondary Prevention, Discharge Antibiotics, and Long-Term Plan

— Step-down to oral when patient is afebrile 48 hr, hemodynamically stable, leukocytosis trending down, tolerating PO, source controlled

— Bioavailable orals (fluoroquinolones, linezolid, TMP-SMX, metronidazole, doxycycline) often equivalent to IV

— OPAT (outpatient parenteral antibiotic therapy): indicated when prolonged IV needed (S. aureus bacteremia, osteomyelitis, endocarditis, deep prosthetic infection); requires PICC, weekly labs (CBC, BMP, drug levels), ID follow-up

— Total duration: 4–7 days for uncomplicated intra-abdominal SSI with source control; 4–6 weeks IV for osteomyelitis, mediastinitis, prosthetic infection; suppressive oral antibiotics in selected retained-implant cases

— Written instructions on dressing changes, signs of worsening (expanding redness, fever, increased drainage)

— Visiting nurse for NPWT or complex wound care

— Patient/caregiver hand hygiene training

— Optimize HbA1c to <7% before next elective procedure

— Smoking cessation counseling and nicotine replacement

— Weight management if obesity contributed

— Document MRSA colonization status; pre-decolonize before next surgery

— Update vaccinations (pneumococcal, influenza, COVID, Tdap) once recovered

— Stop unnecessary antibiotics, PPIs (C. diff risk), opioids (transition to multimodal analgesia)

— Resume home medications stopped perioperatively (DOACs, immunosuppressants, biologics)—timing per disease and bleeding risk

— Counsel on drug interactions (e.g., fluoroquinolone–warfarin INR ↑)

Step 3 management: Every SSI discharge needs an antibiotic stop date in writing. Open-ended antibiotic prescriptions ("take until gone, then call us") drive resistance, C. diff, and readmission. Define duration, follow-up labs, and the date IV access can be removed.

Discharge antibiotic planning:

Wound care at home:

Secondary prevention for future surgeries:

Medication reconciliation at discharge:

Communication: structured handoff to primary care and surgeon with culture results, antibiotic plan, follow-up schedule.

Follow-Up, Monitoring Parameters, and Counseling

— 48–72 hours after discharge (in-person or telehealth with wound photos) for early reassessment

— 7–14 days with surgeon for wound check, staple/suture removal, NPWT adjustments

— 4–6 weeks for resolution confirmation, secondary intention healing progress

— 3 months for implant-related infections to confirm cure; longer for prosthetic joint/vascular graft cases

— Clinical: wound appearance (erythema border, drainage, granulation), pain, temperature, functional recovery

— Labs while on antibiotics:

– CBC weekly (linezolid—thrombocytopenia; β-lactams—neutropenia, eosinophilia)

– BMP weekly (vancomycin, aminoglycosides, TMP-SMX—creatinine, potassium)

– LFTs every 1–2 weeks (oxacillin, ceftriaxone, TMP-SMX)

– Vancomycin AUC or trough every 2–3 days inpatient, then weekly OPAT

– CRP trend for deep infections (downward = response)

— Imaging: repeat CT/MRI for organ-space or implant infections if clinical concern

— Physical therapy for prolonged immobilization

— Pulmonary toilet (incentive spirometry) to prevent pneumonia

— Nutrition follow-up; protein 1.2–1.5 g/kg/day during healing

— When to call: fever >38.3°C, increasing redness/drainage, wound opening, severe pain, calf swelling, shortness of breath

— Activity restrictions (lifting limits for abdominal/hernia repairs typically 6–8 weeks)

— Smoking and alcohol cessation reinforcement

— Glycemic control as ongoing project

— Vaccination updates once acute illness resolved

Board pearl: A vancomycin trough of 18–20 mcg/mL has been replaced by AUC/MIC 400–600 mg·hr/L target in current IDSA guidance—reduces nephrotoxicity. On vignettes featuring vancomycin AKI, the answer is often "AUC-guided dosing" or "switch to alternative agent."

Follow-up cadence:

Monitoring parameters:

Rehabilitation and functional recovery:

Counseling content:

Quality measures: track SSI rate (NHSN reporting), readmission, antibiotic duration, time to source control.

Ethical, Legal, and Patient Safety Considerations

— SSI must be discussed in preoperative consent as a known complication, with quoted institutional or procedure-specific rates

— When SSI occurs, transparent disclosure ("open and honest communication") to patient and family is the ethical and legal standard—most state CANDOR and apology laws protect such disclosures

— Document conversations contemporaneously

— Retained surgical items (sponges, instruments) presenting as deep SSI weeks later → CMS "never event"; mandatory root cause analysis and disclosure

— Wrong-site surgery, fire, air embolism also CMS never events—surgical safety implications overlap

— Universal Protocol/timeout (correct patient, site, procedure, antibiotics, equipment) is mandatory before incision

— Handoff failures between OR-PACU-ward-discharge are the #1 source of postop antibiotic and wound-care errors

— Use structured handoff tools (I-PASS, SBAR) and explicit antibiotic stop dates

— Reconcile medications at every transition

— Discharge before tolerating wound care is a known readmission driver—ensure home health is set up before discharge

— Surveillance reporting to NHSN/state health departments for SSI rates per CMS requirements

— Public reporting on Hospital Compare affects reimbursement (value-based purchasing, HAC reduction program)

— Suspected outbreak (cluster of unusual organisms) → infection prevention and public health notification

— Avoid unnecessary or prolonged antibiotics; track DDD (defined daily doses) and broad-spectrum days of therapy

— Engage stewardship team for OPAT planning

— For elective procedures in high-risk patients (frailty, HbA1c >9), document risk-benefit discussion and shared decision-making about delaying for optimization

Step 3 management: A postop nursing-home patient develops SSI; the family asks if "this could have been prevented." The correct response is transparent disclosure of what happened, what is being done, and what will be reviewed—not defensive deflection. Honest communication reduces malpractice claims and respects patient autonomy.

Informed consent and disclosure:

Patient safety and never events:

Transitions of care:

Mandatory reporting:

Resource stewardship and antimicrobial stewardship:

Capacity and shared decision-making:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When a vignette mentions a patient who shaved with a razor the night before surgery or had glucose 240 mg/dL intraoperatively, the cause of the inevitable SSI is the modifiable risk factor—answer the prevention question accordingly.

Top 3 SSI organisms overall: S. aureus (incl. MRSA), CoNS, E. coli.

Cardiac surgery deep sternal infection: S. aureus, CoNS; consider mupirocin nasal decolonization preop.

Colorectal SSI: polymicrobial, especially B. fragilis + E. coli; oral neomycin/erythromycin + mechanical bowel prep + IV cefoxitin reduces incidence.

Hysterectomy: vaginal flora + GI flora; cefazolin prophylaxis; chlorhexidine vaginal prep.

Shoulder arthroplasty: Cutibacterium acnes—hold cultures 14 days; chronic indolent course.

Hot tub/water exposure post-skin surgery: Pseudomonas folliculitis.

Cat/dog bite wound: Pasteurella multocida; amoxicillin-clavulanate.

Human bite/fight wound: Eikenella corrodens; amoxicillin-clavulanate.

Salt water: Vibrio vulnificus—doxycycline + ceftriaxone, especially in cirrhotics.

Fresh water: Aeromonas hydrophila.

Necrotizing fasciitis Type I: polymicrobial (diabetics, perineum—Fournier gangrene); Type II: group A strep ± S. aureus.

Clostridial myonecrosis (gas gangrene): C. perfringens; penicillin + clindamycin.

Surgical timing of prophylaxis: within 60 min of incision (120 min vancomycin/fluoroquinolone); intraop redose at 2× drug half-life or significant blood loss; discontinue within 24 hr of close.

Hair removal: clippers, not razors; razors ↑ SSI by ~2×.

Skin prep: alcohol-chlorhexidine > povidone-iodine for most surgeries.

Glucose target perioperative: 110–180 mg/dL; >200 doubles SSI risk.

Normothermia (core >36°C) and normoxia reduce SSI.

Smoking cessation ≥4 weeks before elective surgery.

Mesh/vascular graft/prosthesis window: SSI defined up to 90 days post-op.

CRP rising after POD 4 suggests SSI.

LRINEC ≥6: consider necrotizing fasciitis; ≥8 high risk.

Vancomycin dosing: AUC/MIC 400–600 mg·hr/L target; 15 mg/kg load.

STOP-IT trial: 4 days of antibiotics suffices for adequately source-controlled intra-abdominal infection.

Board Question Stem Patterns

CCS pearl: When a CCS case offers "IV vancomycin" as a default for any postop fever, pause—ask whether the patient has MRSA risk and whether you've drained the source. Empiric vancomycin without source control or without MRSA risk is often wrong.

Pattern 1 — Postop fever timeline (the 5 W's): "POD 5, fever 38.6°C, incisional erythema and drainage" → SSI. POD 1–2 fever in well patient → atelectasis/cytokine release, no workup needed.

Pattern 2 — Prophylactic antibiotic timing: "Cefazolin given 2 hours before incision" → wrong; should be within 60 min. Or "redosing not done for 5-hour case" → wrong; redose at 4 hr for cefazolin.

Pattern 3 — β-lactam allergy with rash only: answer is still cefazolin (cross-reactivity <2%), not clindamycin.

Pattern 4 — Diabetic with HbA1c 9.5 for elective surgery: delay and optimize; don't proceed.

Pattern 5 — Razor shave the night before: clippers immediately before incision is the correct prevention.

Pattern 6 — Necrotizing fasciitis vignette: pain out of proportion, bullae, crepitus, septic → emergent OR debridement + vancomycin + piperacillin-tazobactam + clindamycin, not CT first.

Pattern 7 — Intra-abdominal abscess on CT POD 7: percutaneous drainage + culture-directed antibiotics, not antibiotics alone.

Pattern 8 — S. aureus bacteremia from wound: TTE (TEE if implant/persistent), repeat blood cultures, 14-day minimum IV antibiotics, ID consult.

Pattern 9 — Patient on chronic prednisone with refractory hypotension postop: stress-dose hydrocortisone—adrenal insufficiency, not SSI.

Pattern 10 — Persistent draining sinus over hip arthroplasty 3 months postop: prosthetic joint infection → ESR/CRP, joint aspiration, two-stage exchange.

Pattern 11 — Cefepime + vancomycin AKI: switch vancomycin to AUC-guided dosing or alternative; consider linezolid/daptomycin for MRSA coverage.

Pattern 12 — Mediastinitis post-CABG: sternal instability, fever, drainage → CT, OR debridement, vancomycin + broad-spectrum, often muscle flap reconstruction.

Pattern 13 — Bowel surgery + POD 5 fever, tachycardia, leukocytosis, no wound findings: suspect anastomotic leak, CT with contrast.

Pattern 14 — C. diff after broad-spectrum antibiotics: PO vancomycin or fidaxomicin; stop unnecessary antibiotics.

One-Line Recap

Surgical site infection is best treated by being prevented—through perioperative glucose control, timely weight-based prophylactic antibiotics within 60 minutes of incision and stopped within 24 hours, chlorhexidine-alcohol skin prep with clippers (never razors), normothermia, and MRSA decolonization for high-risk procedures—and when it occurs, source control (open the wound, drain the abscess, debride necrotic tissue, remove infected hardware when indicated) precedes and outweighs antibiotic choice in every clinical decision.

Board pearl: The single most testable concept on Step 3 SSI questions is that source control beats antibiotic escalation—every time a vignette offers "broaden coverage" versus "open the wound, drain the abscess, or take to the OR," the procedural answer is correct unless the patient is unstable enough to need both simultaneously.

Prevent: glucose 110–180, smoking cessation 4 wk, mupirocin + CHG for cardiac/ortho-implant, cefazolin within 60 min, clippers not razors, alcohol-CHG prep, normothermia, antibiotic stop within 24 hr of close.

Diagnose: Wound (POD 5–7) is the most likely "W"; deep tissue culture (not surface swab); CT for organ-space; blood cultures and lactate if systemic; LRINEC + clinical gestalt for necrotizing infection.

Treat: open and drain superficial wounds; emergent OR for necrotizing infections with vancomycin + pip-tazo + clindamycin; percutaneous drainage for deep collections; DAIR for early PJI, two-stage exchange for chronic PJI; STOP-IT 4-day course post-source-control for intra-abdominal infections; vancomycin AUC-guided 400–600 mg·hr/L.

Transition: define antibiotic stop date in writing, structured handoff to PCP and surgeon, 48–72 hr follow-up, OPAT with weekly labs for prolonged IV therapy, transparent disclosure when complications arise, optimize modifiable risk factors before any future elective procedure.